Company: ANTX
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0000950170-25-107301
Chunk: 9

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-08-12
Form: 10-Q
Item: Item 5
Chunk 9
---
On April 17, 2025, MGC Venture Partners 2018, LP, whose managing director is one of our directors, Dr. Rob Readnour, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 582,288 shares of our common stock until August 15, 2026.

On April 17, 2025, MGC Venture Partners QP 2018, LP, whose managing director is one of our directors, Dr. Rob Readnour, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 652,573 shares of our common stock until August 15, 2026.